NCM · Biotechnology

CUE (CUE) Stock

$32.57 +1.40% NCM: CUE Healthcare

Valuation

MetricValue
Price$32.57
Market Cap$85.59M
P/E Ratio-4.05
P/B Ratio4.37
P/S Ratio1.86
EPS (TTM)$-8.40
52-Week High$41.42
52-Week Low$4.98
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-103.85%
ROA-64.29%
ROCE-103.85%
Gross Margin-100.00%
Operating Margin-100.00%
Net Margin-59.65%
Debt/Equity0.16
Current Ratio2.85

Annual Financials (USD)

Metric20212022202320242025
Revenue$15.0M$1.0M$5.0M$9.0M$27.0M
Operating Profit$-44.0M$-53.0M$-52.0M$-41.0M$-27.0M
Net Profit$-44.0M$-53.0M$-51.0M$-41.0M$-27.0M
EPS$-42.30$-44.70$-33.30$-21.60$-8.40
Op Margin-292.6%-4275.1%-949.9%-446.9%-96.7%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$83.0M$91.0M$62.0M$32.0M$42.0M
Total Liabilities$18.0M$26.0M$24.0M$15.0M$16.0M
Cash$64.0M$52.0M$49.0M$22.0M$27.0M
Borrowings$12.0M$19.0M$15.0M$9.0M$4.0M

Latest News

Head and Neck Squamous Cell Carcinoma Market is Projected to Boost at a CAGR of 10.5% During the Forecast Period (2026–2036) Due to the Launch of Emerging Novel Immunotherapies | DelveInsight GlobeNewswire · Jul 13, 2026 Cue Biopharma Appoints Dominic Borie, M.D., Ph.D., as Chief Medical Officer and Head of Research & Development GlobeNewswire · Jul 13, 2026 Top Midday Gainers MT Newswires · Jul 10, 2026 Cue Biopharma Announces $50 Million Private Placement MT Newswires · Jul 10, 2026 Cue Biopharma Announces $50.0 Million Private Placement GlobeNewswire · Jul 10, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-39.0M$-42.0M$-40.0M$-36.0M$-22.0M
Investing Cash Flow$8.0M$-25.0M$25.0M$0$0
Financing Cash Flow$2.0M$4.0M$0$0$0
Net Cash Flow$-10.0M$-13.0M$-3.0M$-26.0M$5.0M
Free Cash Flow$-40.0M$-42.0M$-40.0M$-36.0M$-22.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-40.36%
Quick Ratio3.57
Interest Coverage—
Return 1Y42.69%
Return 3Y-77.55%
Return 5Y-90.15%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
BRNSBarinthus Biotherapeutics plc $0.67 +4.69% -0.41 — 0.00%
COEPCoeptis Therapeutics Holdings, Inc. $10.99 -8.57% -4.45 $38.62M 0.00%
EQ $2.57 +3.21% -5.28 $91.29M 0.00%
IOBTIO Biotech, Inc. $0.01 -27.59% -0.01 $885690 0.00%
IPSC $2.02 -1.46% -5.04 $174.87M 0.00%

About CUE

CUE is led by CEO Lucinda Warren, employs 41 people, headquartered in US, publicly traded since 2018.

CUE stock trades at $32.57 with a market capitalization of $85.59M. The stock is valued at a price-to-earnings (P/E) ratio of -4.05, price-to-book of 4.37, price-to-sales of 1.86. Over the past 52 weeks the stock has ranged between $4.98 and $41.42, and currently trades 21.4% below its 52-week high.

On profitability, CUE generates a return on equity (ROE) of -103.85%, return on capital employed of -103.85%, an operating margin of -100.00%, a net profit margin of -59.65%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides